Stakeholders brace for bumps in rare pediatric disease PRV reauthorization
A voucher program designed to stimulate drug development for rare pediatric diseases will sunset later this year if lawmakers don’t reauthorize it — and rare disease …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
